Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

CD 15 (C3D‐1) Immunoreactivity in Normal, Benign, and Malignant Thyroid Lesions

CD 15 (C3D‐1) Immunoreactivity in Normal, Benign, and Malignant... A variety of antibodies detect the antigen defined by the cluster designation group 15 (CD15). These antibodies have been reported to be helpful in the diagnosis of many different diseases, including leukemia. Hodgkin's disease, non-Hodgkin's lymphoma, and many carcinomas. We compared the expression of monoclonal antibody CD15 (C3D-1) in a group of thyroid neoplasms to determine whether there were differences in the expression of CD15 in various tumor types. Twenty samples representing normal thyroid tissues. 15 Graves' disease. 17 Hashimoto's disease, 15 adenomatous goiter, 30 follicular adenoma, 25 follicular carcinoma, 72 papillary carcinoma, 10 medullary carcinoma, and 18 undifferentiated carcinoma were analyzed by immunohistochemistry. Sixty-one (84.7%) of 72 cases of papillary carcinoma were positive for CD15 immunostaining. The other lesions were CD15-negative except for 1 (4.0%) of the 25 follicular carcinomas and 2 (20.0%) of the 10 medullary carcinomas. Our results indicate that CD15 may be used as a marker for papillary carcinoma of the thyroid gland. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

CD 15 (C3D‐1) Immunoreactivity in Normal, Benign, and Malignant Thyroid Lesions

Loading next page...
 
/lp/wolters-kluwer-health/cd-15-lpar-c3d-hyphen-1-rpar-immunoreactivity-in-normal-comma-benign-FmS2d0UoZY

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1062-3345
eISSN
1533-4058

Abstract

A variety of antibodies detect the antigen defined by the cluster designation group 15 (CD15). These antibodies have been reported to be helpful in the diagnosis of many different diseases, including leukemia. Hodgkin's disease, non-Hodgkin's lymphoma, and many carcinomas. We compared the expression of monoclonal antibody CD15 (C3D-1) in a group of thyroid neoplasms to determine whether there were differences in the expression of CD15 in various tumor types. Twenty samples representing normal thyroid tissues. 15 Graves' disease. 17 Hashimoto's disease, 15 adenomatous goiter, 30 follicular adenoma, 25 follicular carcinoma, 72 papillary carcinoma, 10 medullary carcinoma, and 18 undifferentiated carcinoma were analyzed by immunohistochemistry. Sixty-one (84.7%) of 72 cases of papillary carcinoma were positive for CD15 immunostaining. The other lesions were CD15-negative except for 1 (4.0%) of the 25 follicular carcinomas and 2 (20.0%) of the 10 medullary carcinomas. Our results indicate that CD15 may be used as a marker for papillary carcinoma of the thyroid gland.

Journal

Applied Immunohistochemistry & Molecular MorphologyWolters Kluwer Health

Published: Jan 1, 1998

There are no references for this article.